- Home
- KRRO vs PLX Comparison
KRRO vs PLX Comparison
Compare KRRO & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRRO
- PLX
- Stock Information
- Founded
- KRRO 2014
- PLX 1993
- Country
- KRRO United States
- PLX United States
- Employees
- KRRO N/A
- PLX N/A
- Industry
- KRRO Biotechnology: Pharmaceutical Preparations
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KRRO Health Care
- PLX Health Care
- Exchange
- KRRO Nasdaq
- PLX Nasdaq
- Market Cap
- KRRO 147.4M
- PLX 127.4M
- IPO Year
- KRRO 2019
- PLX 1998
- Fundamental
- Price
- KRRO $33.22
- PLX $1.86
- Analyst Decision
- KRRO Strong Buy
- PLX Strong Buy
- Analyst Count
- KRRO 7
- PLX 1
- Target Price
- KRRO $96.71
- PLX $15.00
- AVG Volume (30 Days)
- KRRO 237.0K
- PLX 712.2K
- Earning Date
- KRRO 11-11-2025
- PLX 11-13-2025
- Dividend Yield
- KRRO N/A
- PLX N/A
- EPS Growth
- KRRO N/A
- PLX N/A
- EPS
- KRRO N/A
- PLX 0.08
- Revenue
- KRRO $6,281,000.00
- PLX $61,948,000.00
- Revenue This Year
- KRRO $97.27
- PLX $14.53
- Revenue Next Year
- KRRO N/A
- PLX $75.77
- P/E Ratio
- KRRO N/A
- PLX $23.95
- Revenue Growth
- KRRO N/A
- PLX 62.79
- 52 Week Low
- KRRO $10.29
- PLX $0.99
- 52 Week High
- KRRO $98.00
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- KRRO 67.72
- PLX 63.02
- Support Level
- KRRO $30.36
- PLX $1.52
- Resistance Level
- KRRO $37.03
- PLX $1.97
- Average True Range (ATR)
- KRRO 3.68
- PLX 0.09
- MACD
- KRRO -0.07
- PLX 0.03
- Stochastic Oscillator
- KRRO 77.36
- PLX 74.44
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.